Matrixyl (Palmitoyl Pentapeptide-4)

Typical use cases

Dosing guidelines

Titration

No medical titration applies to a topical cosmetic; community guidance generally describes introducing the product gradually (e.g., once daily for the first week, then twice daily) to assess skin tolerance.

Reconstitution

N/A — supplied as a finished leave-on topical serum/cream or as a raw cosmetic ingredient blended (not injected) into a base; not reconstituted for injection.

Injection sites

N/A — topical application to clean, dry skin (commonly the face, periorbital/crow's-feet area, forehead, and neck); not an injectable compound.

Storage & handling

Store sealed away from heat, light, and air; finished cosmetic products are typically kept at room temperature, while raw peptide powder is best stored cool/refrigerated and protected from moisture to limit peptidase and oxidative degradation.

Side effects

• Mild skin irritation or redness at application site Mild · Uncommon
• Dryness or transient stinging Mild · Uncommon
• Contact allergy / sensitization Moderate · Rare
• Itching Mild · Rare
• Acneiform breakout (often attributable to occlusive vehicle rather than the peptide) Mild · Rare

Research summary

Palmitoyl Pentapeptide-4 (Pal-KTTKS) is a synthetic matrikine: the pentapeptide sequence Lys-Thr-Thr-Lys-Ser is a fragment of type I procollagen, conjugated to palmitic acid to improve lipophilicity and skin penetration. Mechanistically it is reported to act as a feedback signal that prompts dermal fibroblasts to upregulate synthesis of extracellular-matrix components including collagen types I, III and IV, fibronectin, and glycosaminoglycans; this is supported primarily by in vitro fibroblast culture work. The most cited human evidence is Robinson et al. (International Journal of Cosmetic Science, 2005), a 12-week double-blind, placebo-controlled, split-face study in 93 women comparing a moisturizer with 3 ppm pal-KTTKS against the vehicle, which found significant reduction in fine lines/wrinkles by technical image analysis and expert grading, with the peptide being well tolerated. Smaller and manufacturer-associated studies have reported reductions in wrinkle depth, volume, and skin roughness, and a later randomized comparison versus acetyl hexapeptide-3 (Argireline) found both peptides improved crow's-feet over baseline. Limitations are notable: many supporting studies are small, industry-sponsored, or use proprietary blends (e.g., Matrixyl 3000, a distinct combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7), and findings do not always transfer between formulations. There is essentially no rigorous evidence for injectable, oral, or systemic use; the compound is characterized and regulated as a leave-on topical cosmetic ingredient. The U.S. Cosmetic Ingredient Review panel has assessed palmitoyl pentapeptide-4 and related pentapeptides as safe as used in cosmetics, with topical irritation and sensitization reported as low.

Key references

• https://pubmed.ncbi.nlm.nih.gov/18492182/
• https://pubchem.ncbi.nlm.nih.gov/compound/9897237
• https://en.wikipedia.org/wiki/Palmitoyl_pentapeptide-4
• https://www.cir-safety.org/sites/default/files/SLR_Pentapeptide4_062023.pdf
• https://pmc.ncbi.nlm.nih.gov/articles/PMC6171572/

Related compounds